Mitonafide (0.5 and 1 mg/kg, i.p., 1-7 days) shows antitumoral potency in S-180 bearing mice[4].
Mitonafide (5 mg/kg, i.p., twice a day) shows anticancer activity in HepG2 xenograft model[6].
Mitonafide (single i.p. injection, S-180 bearing mice) shows the LD50 value of 10.0 mg/kg[5].
| Animal Model: | S-180 bearing mice[4] |
| Dosage: | 0.5 mg/kg and 1 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) for 1-7 days |
| Result: | Increased in median survival times. |
| Animal Model: | HepG2 xenograft model [6] |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), twice a day. |
| Result: | Exhibited a relative tumor increment rates (T/C) value of 28.8%. |
